Anti-CD19 Antibody (Tafasitamab) is an Fc-engineered humanized monoclonal antibody that specifically targets the CD19 antigen on B lymphocytes. The compound mediates potent antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) by enhanced binding to Fcgamma receptors on effector cells, thereby directly inducing cell death and depleting malignant B cells. It serves as a pharmacological tool for investigating diffuse large B-cell lymphoma (DLBCL) and other B-cell malignancies.
Target:
Immunology/Inflammation related
T9901A-1348
* VAT and and shipping costs not included. Errors and price changes excepted
